COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA

PHASE4CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

June 8, 2018

Primary Completion Date

July 1, 2022

Study Completion Date

July 1, 2022

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Etanercept 50 MG/ML

Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme

DRUG

Leflunomide 10 milligram (MG)

Leflunomide 10mg PO daily added to the COBRA-Slim scheme

Trial Locations (19)

1000

CHU Saint Pierre, Brussels

Cliniques Universitaire Saint Luc (UCL), Brussels

1070

Hôpital Erasme-ULB, Brussels

1090

UZ Brussel, Brussels

1800

AZ Jan Portaels, Vilvoorde

2170

ZNA Jan Palfijn, Merksem

2200

AZ Herentals, Herentals

2820

Imelda Ziekenhuis Bonheiden, Bonheiden

3000

Regionaal Ziekenhuis Heilig Hart Leuven, Leuven

UZ Leuven, Leuven

3500

Reuma Instituut Hasselt, Hasselt

3600

Reuma centrum Genk, Genk

Reuma Clinic Genk, Genk

4000

CHU Liège, Liège

5530

CHU UCL Namur ASBL Site Godinne, Yvoir

6060

GHdC Saint Joseph, Gilly

8000

AZ Sint Jan Brugge, Bruges

8310

AZ St Lucas Brugge, Bruges

9300

OLV Ziekenhuis Aalst, Aalst

All Listed Sponsors
collaborator

Belgium Health Care Knowledge Centre

OTHER_GOV

lead

P. Verschueren

OTHER

NCT03649061 - COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA | Biotech Hunter | Biotech Hunter